Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes.

摘要: Abstract Leishmaniasis is a complex tropical disease caused by kinetoplastid parasitic protozoa of the genus Leishmania and transmitted sand fly insect vector. Cutaneous leishmaniasis (CL) most common form this disease, CL infections often result in serious skin lesions scars. remains public health problem many endemic countries worldwide because absence effective, safe, cost-effective drugs for treatment. One strategies we chose to use find novel chemical entities worthy further development as antileishmanials involved screening synthetic natural products libraries. In our study, developed major intracellular amastigote assay that uses activity luciferase measure parasite proliferation used screen collection 400 compounds obtained from Medicines Malaria Venture (MMV) their antileishmanial activity. Our results showed 14 identified MMV antimalarial have can potentially be optimized drug development.